Who are BICALUTAMIDE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Talazoparib with enzalutamide, Winlevi, Xtandi, Xtandi, Nilandron, Casodex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl409.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BICALUTAMIDE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BICALUTAMIDE (BICALUTAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen Receptor Inhibitor [EPC].

marketed Androgen Receptor Inhibitor [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

BICALUTAMIDE (BICALUTAMIDE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BICALUTAMIDE TARGET	BICALUTAMIDE		marketed	Androgen Receptor Inhibitor [EPC]		1995-01-01
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Winlevi	CLASCOTERONE	Sun Pharma	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2020-01-01
Xtandi	enzalutamide	Astellas Pharma	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2012-01-01
Xtandi	xtandi	Astellas Pharma	marketed	Androgen receptor inhibitor	Androgen receptor	2012-01-01
Nilandron	NILUTAMIDE	Advanz	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	1996-01-01
Casodex	bicalutamide	ANI Pharmaceuticals	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	1995-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-08-24 — Xtandi · 8183274 · US
2027-08-13 — Xtandi · 7709517 · US

Sponsor landscape (Androgen Receptor Inhibitor [EPC] class)

· 1 drug in this class
ANI Pharmaceuticals · 1 drug in this class
Advanz · 1 drug in this class
Astellas Pharma · 1 drug in this class
Pfizer Inc. · 1 drug in this class
Sun Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BICALUTAMIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl409. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing